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Recently, we reported a novel series of neurological com-pounds1 that merged key pharmacophores found in two
classes of clinical neurological agents, functionalized amino
acids (FAAs, 2)210 and R-amino acid amides (AAAs, 3),1115
into the concise structure 1 (Figure 1). Lacosamide10 (Vimpat,
(R)-4) is the prototypical FAA and is a first-in-class antiepileptic
drug (AED) that is marketed in the United States and Europe for
adjunctive treatment of partial onset seizures in adults.16 Safina-
mide ((S)-5) and ralfinamide ((S)-6) are representative AAAs,
and both have undergone extensive clinical trials.1115 While
(S)-512,13 and (S)-614,15 are potent anticonvulsants, Merck-
Sorono has advanced (S)-5 for the treatment of Parkinson’s
disorders, andNewron has evaluated (S)-6 for neuropathic lower
back pain. Recent, late-stage human clinical trials have indicated
that neither (S)-5 nor (S)-6 met their clinical end points,
although they exhibited no undesirable side effects.17,18
At first glance, 2 and 3 appear similar in structure due to the
vicinal diamine backbone that contains a carbonyl (CdO)
moiety, the presence of one chiral center, and the inclusion of
aN-benzyl (PhCH2)-type substituent. Pharmacologically, (R)-4,
(S)-5, and (S)-6 exhibited excellent seizure protection10,19,20 in
the maximal electroshock seizure (MES) animal model,21 and
electrophysiology studies demonstrated that these agents modu-
lated sodium currents.13,15,22,23 However, (R)-4 selectively
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ABSTRACT:We recently reported that merging key structural
pharmacophores of the anticonvulsant drugs lacosamide
(a functionalized amino acid) with safinamide (anR-aminoamide)
resulted in novel compounds with anticonvulsant activities
superior to that of either drug alone. Here, we examined the
effects of six such chimeric compounds on Naþ-channel func-
tion in central nervous system catecholaminergic (CAD) cells.
Using whole-cell patch clamp electrophysiology, we demon-
strated that these compounds affected Naþ channel fast and
slow inactivation processes. Detailed electrophysiological char-
acterization of two of these chimeric compounds that contained
either an oxymethylene ((R)-7) or a chemical bond ((R)-11)
between the two aromatic rings showed comparable effects on
slow inactivation, use-dependence of block, development of
slow inactivation, and recovery of Naþ channels from inactiva-
tion. Both compounds were equally effective at inducing slow
inactivation; (R)-7 shifted the fast inactivation curve in the
hyperpolarizing direction greater than (R)-11, suggesting that
in the presence of (R)-7 a larger fraction of the channels are in
an inactivated state. None of the chimeric compounds affected veratridine- or KCl-induced glutamate release in neonatal cortical
neurons. There was modest inhibition of KCl-induced calcium influx in cortical neurons. Finally, a single intraperitoneal
administration of (R)-7, but not (R)-11, completely reversed mechanical hypersensitivity in a tibial-nerve injury model of
neuropathic pain. The strong effects of (R)-7 on slow and fast inactivation ofNaþ channels may contribute to its efficacy and provide
a promising novel therapy for neuropathic pain, in addition to its antiepileptic potential.
KEYWORDS: Lacosamide, safinamide, sodium channel, slow/fast inactivation, state-dependent, neuropathic pain
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enhanced the slow-inactivation state of the voltage-gated sodium
channel (VGSC),22,23 while (S)-5 inhibited tetrodotoxin-sensi-
tive (TTX-S) fast sodium currents,13,24 and (S)-6 modulated
both sodium channel fast and slow inactivation processes.15 The
structural differences in (R)-4, (S)-5, and (S)-6 account for their
different modes of action and underscore that each compound
has distinctive pharmacophores that contribute to drug function.
We demonstrated that several 1s displayed anticonvulsant
activity in theMES seizuremodel that exceeded (R)-4, (S)-5, and
established AEDs,25 and exhibited pronounced activities in
neuropathic pain animal models.1 In this study, we evaluated
selected 1s by whole-cell, patch-clamp electrophysiology in
catecholamine A differentiated (CAD) cells26,27 and report their
receptor binding profiles against a broad panel of neurological
receptors. We find that while 1, like (R)-4,27 enhanced entry into
the sodium channel slow-inactivation state, they were far more
potent than (R)-4 in facilitating this transformation. Moreover,
we show that, by varying the structure in 1, sodium channel slow-
and fast-inactivation processes can be modulated. When the 1s
were evaluated against a panel of 44 receptors known to impact
drug effectiveness, we observed no significant binding. Similarly,
the 1s did not affect hERG Kþ channel activity. The potential
neuropathic pain properties of two chimeric 1 agents were
evaluated in a rat tibial-nerve injury (TNI) model.28 Collectively,
our pharmacological data indicate that 1s exhibit a distinctive
blend of pharmacological activities, providing compounds of
neurological significance.
’RESULTS AND DISCUSSION
Structurally, 1s can be viewed as consisting of three compo-
nents (Figure 1, sectors AC in 1). The first is the N-acetyl
amino acid N0-benzyl amide unit (sector A) seen in 2. The
second is the linker (X-Y-Z, sector B) that connects the two aryl
group. This moiety is present in 229 and 3. The final group is the
terminal aromatic ring (sector C) seen in 3. In our 1 structure
activity relationship (SAR) study, we varied one of these three
components while retaining the same structural features seen in
either (R)-4 or (S)-5 for the other two groups.1 The anti-
convulsant activities for the compounds were determined in
the MES and the subcutaneous Metrazol30 (scMet) tests at
the National Institute of Neurological Disorders and Stroke
(NINDS) Anticonvulsant Screening Program (ASP). Several
structural principles emerged from this study. First, in sector A,
successive increases in the size of the R group led to decreased
anticonvulsant activity in the MES test. Second, including a
substituted heteroatom one atom removed from the C(2) chiral
center led to increased activity. Third, the observed anticonvul-
sant activity for 1 in the MES test principally resided in the
D-configuration ((R)-stereoisomer). These three structural pat-
terns were similar to those discovered for 2.210 Sector B
consisted of the linker XYZ unit. XYZ is a molecular
unit 13 atoms long, or it could also be a single bond. In sector B,
we found that the most potent 1 derivatives in the MES test were
those in which XYZwas a single bond, a rigid, linear (alkyne)
unit, or a short moiety (O; XY, where X and Y are C(H),
N(H), O, and CH2). For sector C, we found that the anti-
convulsant activity could be altered several-fold by the substi-
tuent pattern in the terminal aryl (Ar) group. Both 1s0 chiral
preference for the (R)-stereoisomer for blockage of MES-in-
duced seizures and the absence of scMet seizure protection are
hallmarks of FAA activity.210 By comparison, (S)-5 and its
stereoisomer (R)-5 have nearly equivalent activities in the MES
test,11,31 and (S)-5,32 unlike 1,1 (R)-4,10 or 2,29 displayed
notable activity in the scMet model.
Compound Selection. Six 1s (Table 1, compounds (R)-7,
(S)-7, (R)-8, (R)-9, (R)-10, (R)-11) were examined by whole-
cell, patch-clamp electrophysiology in CAD cells. For sector A in
1, we selected the (R)-N-benzyl 2-acetamido-3-methoxypropio-
namide motif seen in (R)-4 since this unit exhibited the best
activity in our SAR investigation.1 Three units were chosen for
sector B. They were the oxymethylene (OCH2) unit seen in both
(S)-5 and (S)-6, the isomeric methyleneoxy (CH2O) unit, and
the unit in which the ether linkages were deleted to give a
chemical bond. For the terminal aryl unit, we selected com-
pounds that were fluorinated at the 200 (similar to (S)-6) or the
300 (similar to (S)-5) position or was unsubstituted. Finally, we
prepared the (R)- and (S)-enantiomers for a 1 derivative to
provide information on the role of stereochemistry in cellular and
receptor binding pharmacology. Significantly, (R)-7, (R)-8,
(R)-9, (R)-10, and (R)-11 all exhibited excellent anticonvulsant
activities in the MES seizure model21 in rodents (ip, po),
activities comparable to (R)-4 and that exceeded other antiepi-
leptic drugs (Table 1).
Chemistry. Syntheses of (R)-7, (S)-7, (R)-8, (R)-9, and
(R)-11 were previously reported.1 We prepared (R)-10 using a
method similar to the one for its isomer (R)-9 and using amine
15 and (R)-16 (Scheme 1). All compounds were fully character-
ized, and the enantiopurity of (R)-10 was assessed by detection
of a single acetyl methyl and O-methyl signal in the 1H NMR
spectrum upon addition of a saturated solution of (R)-
()-mandelic acid.33
Receptor-Binding Profiles of Compounds 1s on Human or
Rodent Brain Receptors. Primary radioligand binding profiles
at UNC’s National Institute of Mental Health (NIMH)-funded
Psychoactive Drug Screening Program for 1 compounds were
compared against a panel of 44 receptors and ion channels,
including serotonin, adrenergic, dopamine, GABA, histamine,
muscarinic, opioid, sigma, and transporters, and we saw no
Figure 1. Overlay of pharmacophores in 1. Structures of functionalized
amino acids (2), R-aminoamides (3), and chimeric agents 1. The area of
overlap in 1 (shown in box) permitted incorporating key pharmaco-
phores found in 2 and 3 into a unified structure.
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significant binding at 10 μM of compounds (data not shown).
When the six 1 compounds (10 μM)were evaluated in the hERG
Kþ channel assay using a fluorescence-based membrane poten-
tial assay, no activity was observed (data not shown). Three of
the six (9, 10, 11) exhibited modest binding (∼3146%
displacement at 10 μM) for site 2 sodium channel binding when
tested at Cerep (data not shown).
Robust Inhibition of Naþ Currents by 1 Agents. Using the
whole-cell patch-clamp configuration, we examined the effects of
the six chimeric compounds on voltage-gated Naþ channels in
CAD cells. We have previously shown that CAD cells express
endogenous tetrodotoxin-sensitive Naþ currents with rapid
activation and inactivation upon membrane depolarization and
are likely composed of NaV1.7, NaV1.1, and NaV1.3 channels.
27
We also showed that (R)-4 inhibited peak Naþ currents by
∼40%, while the inactive enantiomer (S)-4 exhibited no inhibi-
tion. Here, the ability of 1 agents to inhibit peak inward Naþ
currents was tested by holding CAD cells at80mV and running
a current (I)voltage (V) protocol, which consisted of 15 ms
step depolarizations ranging from 70 to þ80 mV (inþ10 mV
Table 1. Anticonvulsant and Electrophysiology Data for 1 Agents
aThe compounds were administered intraperitoneally. ED50 and TD50 values are in milligrams per kilogram. Numbers in parentheses are 95%
confidence intervals. The dose effect was obtained at the time of peak effect (indicated in hours in brackets). bMES =maximal electroshock seizure test.
cTD50 value determined from the rotorod test.
dThe compounds were administered orally. ED50 and TD50 values are inmilligrams per kilogram.
eTox =
behavioral toxicity. f IC50, Concentration at which half of the Na
þ channels have transitioned to a slow inactivated state. gReference 10. hReference 1.
iND = not determined. jReference 25. kNo ataxia observed up to 3000 mg/kg. lNS, not selective for slow inactivation. mReferences 22 and 56.
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increments). Figure 2A shows representative peak Naþ currents,
elicited by a step to 0 mV, recorded from CAD cells treated with
0.1% dimethyl sulfoxide (DMSO; predrug control) or highest
concentrations used for each of the 1 agents. All chimeric
compounds greatly inhibited peak Naþ currents at concentra-
tions of 30 μM and higher (Figure 2B). These peaks were
normalized by cell capacitance and were expressed as peak
current density (pA/pF) to account for variations in cell size.
Doseresponse curves for percent inhibition of peak Naþ
currents were constructed and yielded IC50 values, that is, a
concentration at which half of the peak Naþ current is inhibited
(Table 2). These results show that the 1 agents are far better
inhibitors of peak Naþ currents than (R)-4. Naþ current inhibi-
tion was not accompanied by changes in reversal potential, half-
maximal activation, or slope parameters (see Figure 4) for any of
the chimeric derivatives.
1 Agents Affect the Transition to a Slow-Inactivated
State of Naþ Currents in CAD Cells. Consistent with earlier
observations,22,23 we recently reported that (R)-4 reduces VGSC
availability by selectively enhancing the transition to a slow-
inactivated state of VGSCs.27,34 Therefore, we tested the ability
of chimeric 1 to modulate transition to a slow-inactivated state in
CAD cells. CAD cells were held at 80 mV and conditioned
to potentials ranging from 120 to þ20 mV (in þ10 mV
increments) for 5 s. Then, fast-inactivated channels were allowed
Scheme 1. Synthesis of (R)-10
Figure 2. Inhibition of Naþ currents by chimeric 1 derivatives. (A)
Representative peak Naþ current responses, evoked by a step from a
holding potential of 80 to 0 mV, of CAD cells treated with 0.1%
DMSO control (predrug), 30 μM (R)-7, 500 μM (S)-7, 100 μM (R)-8,
(R)-9, or (R)-10, or 30μM(R)-11. These currents illustrate themaximal
inhibition achievable at the highest concentrations used for each 1. (B)
Percent inhibition of peak current density (pA/pF) for the indicated 1s
measured at 0 mV in CAD cells. Inhibition was determined by normal-
izing peak currents in each drug condition to average peak currents
obtained in DMSO-treated cells. Numbers in parentheses are the
number of cells patched per condition. IC50 values of the peak Na
þ
currents are presented in Table 2.
Table 2. Effects of 1 agents on inhibition of peak Naþ current
compd peak inhibition IC50 (μM)
a
(R)-4 132.6 ( 9.8
(S)-4 >500
(R)-7 13.6 ( 4.1
(S)-7 42.9 ( 1.4
(R)-8 1.1 ( 0.4
(R)-9 7.3 ( 2.0
(R)-10 4.9 ( 0.9
(R)-11 2.2 ( 0.9
a IC50 values were calculated by regression analysis from at least five
different concentrations.
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to recover for 150 ms at a hyperpolarized pulse to120 mV, and
the fraction of channels available was tested by a single depolar-
izing pulse, to 0 mV, for 15 ms (Figure 3A, top left). This brief
hyperpolarization allowed the channels to recover from fast
inactivation while limiting recovery from slow inactivation.
A representative family of slow-inactivation traces from CAD
cells treated with 0.1%DMSO (predrug) or various concentrations
of (R)-7, (S)-7, and (R)-8(R)-11 are shown in Figure 3A. For
comparison, representative current traces at 50 mV are high-
lighted. This potential was chosen for three reasons: (1) a large
fraction of channels are undergoing steady-state inactivation,
which involves contributions from slow- and fast-inactivating
pathways35,36 where 50 mV is within the steep voltage-depen-
dence range for each, (2) it is near the resting membrane potential
(RMP) and approaches the action potential firing threshold for
CNS neurons,37 where slow inactivation appears to be physiologi-
cally relevant during sustained subthreshold depolarizations,38 and
(3) changes in the Naþ channel availability near 50 mV can
impact the overlap of Naþ current activating and inactivating under
steady-state conditions.36,39 Adding 30 μM (R)-7 to CAD cells
significantly decreased the fraction of current available, compared
with cells without drug. (S)-7, at the highest dose of 500 μM,
reduced the available current but not to the extent observed with
(R)-7. At50 mV, 0.91( 0.01 fractional units (n = 5) of the Naþ
current were available in DMSO-treated cells, suggesting a large
fraction (0.09( 0.01; calculated as 1 minus the normalized INa) of
the channels transitioned to a nonconducting (slow-inactivated)
state in (R)-1-treated cells (Figure 3B, C). These findings are
consistent with earlier results that showed that (R)-4 promoted
slow inactivation in recombinant hNaV1.7 channels expressed in
HEK cells.23 The similarity of our data to these earlier findings
support our use of CAD cells to elucidate the effects of the chimeric
derivatives on Naþ channel function.
Using this patch-clamp protocol, slow inactivation was
observed at potentials more depolarized than 100 mV for
(R)-7(R)-11 with the exception of (S)-7, for which it was
observed at potentials more depolarized than 80 mV
(Figure 3B). Each of the chimeric 1 agents caused a significant
increase in the maximal fraction of current unavailable by
depolarization (20 mV; control, 0.42 ( 0.02, n = 98; 30 μM
(R)-7, 0.91 ( 0.01, n = 5; 500 μM (S)-7, 0.76 ( 0.02, n = 3;
100 μM (R)-8, 0.93( 0.005, n = 8; 100 μM (R)-9, 0.92( 0.008,
n = 7; 100 μM (R)-10, 0.90 ( 0.007, n = 7; and 30 μM (R)-11,
0.94 ( 0.004, n = 7; p < 0.01, MannWhitney U test).
To further understand the extent to which the hybrid 1 agents
induce slow inactivation, we performed concentration response
curves for slow-inactivation induction for each compound. Using
the Boltzmann equation, we fit the voltage-dependence of slow-
inactivation for control and each of the drug concentrations. This
yielded a V1/2 value of slow inactivation for each concentration
which was then plotted against the concentration used. Finally,
fits of the concentrationresponse of slow inactivation against
the V1/2 of slow inactivation provided an IC50 value. Table 1
shows these values for slow inactivation induced by chimeric 1
Figure 3. 1s affect steady-state slow-inactivation state of Naþ currents in CAD cells. (A) Currents were evoked by 5 s prepulses between120 and20
mV and then fast-inactivated channels were allowed to recover for 150 ms at a hyperpolarized pulse to120 mV. The fraction of channels available at 0
mV was analyzed. Representative current traces from CAD cells in the absence (predrug, 0.1% DMSO) or presence of 1s, as indicated. Illustrated
currents are from concentrations of 1s described in the legend to Figure 2. The dashed traces in each panel represent the current at 50 mV (also
highlighted in the voltage protocol). (B) Summary of steady-state, slow-activation curves for CAD cells treated with DMSO (predrug) or 1 compounds.
Drug-induced slow inactivation was prominent in CAD cells treated with all 1s except (S)-7, which influenced slow inactivation to a lesser extent than the
(R)-enantiomers. (C) Summary of the fraction of current available at50mV for CAD cells in the absence or presence of (R)- or (S)-enantiomers of the
indicated compounds. Asterisks (/) indicate statistically significant differences in fraction of current available between predrug and (R)- and
(S)- compounds (p < 0. 05, Student’s t-test). Hashmark (#) indicates a statistically significant difference in fraction of current available between (R)- and
(S)-enantiomers of 7. Data are from 39 cells per condition, as indicated. The half-maximal values for slow inactivation for all compounds are shown
in Table 1.
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compounds. Compared with our recently reported IC50 calcu-
lated value of 85 μM for slow inactivation induced by (R)-4,27 the
IC50 value for the 1 agents was 16- (for (R)-10) to 53-fold (for
(R)-8 and (R)-9) lower.
Collectively, these data indicate that the chimeric agents (R)-
7(R)-11 are more effective at inducing the transition of Naþ
channels to a slow-inactivated state than is (R)-4.
Figure 4. Activation properties of Naþ currents are not affected by 1
compounds in CAD cells. Values for the voltage of half-maximal
activation (V1/2) and the slope factors (k) were derived from Boltzmann
distribution fits to the individual recordings and averaged to determine
the mean ((SEM) voltage dependence of activation. The voltage
protocol used to evoke current responses is shown in the inset in (A).
Representative Boltzmann fits for 0.03% DMSO (control) and 0.330
μM (R)-11 are shown (A). The V1/2 (B) and k (C) of activation were
not different among the 1 compounds tested (p > 0.05, one-way
ANOVA). Data are from 39 cells per condition.
Figure 5. Fast inactivation properties of Naþ currents are affected by 1
compounds in CAD cells. (A) Voltage protocol for fast inactivation. (B)
Representative current traces showing voltage-dependent fast inactiva-
tion of Naþ currents from CAD cells treated with 0.03% DMSO control
(left). Right: An enlarged region of the inactivating portion of current
traces (from a step to 70 mV) between the arrows from a CAD cell
without drug (0, thick black trace), with 0.3μM(R)-7 (thin broken black
line), or with 30 μM (R)-7 (thick dotted gray line). Note the faster
inactivation in the presence of (R)-7. (C) Representative Boltzmann fits
for 0.03% DMSO (control) and 0.330 μM (R)-7. Values for the
voltage of half-maximal inactivation (V1/2) and the slope factors (k)
were derived from Boltzmann distribution fits to the individual record-
ings and averaged to determine the mean ((SEM) voltage dependence
of steady-state inactivation. (D) Adding increasing concentrations of
(R)-11 led to a hyperpolarizing shift in theV1/2 of fast inactivation. The k
values of steady-state fast inactivation were not different among the
conditions tested (p > 0.05, one-way ANOVA).
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Activation Properties of Naþ Currents in CAD Cells Are
Not Affected by the 1 Agents. Because changes in current
amplitudes can result from changes in channel gating,40 we tested
whether the 1 agents could alter voltage-dependent activation
properties of Naþ currents in CAD cells. Changes in activation
for the CAD cells treated with the derivatives were measured by
whole-cell ionic conductances by comparing their midpoints
(V1/2) and slope factors (k) in response to changes in command
voltage (Figure 4A, inset). Representative Boltzmann fits for
DMSO (predrug) and 0.330 μM (R)-11 are shown in
Figure 4A. An analysis of (R)-7(R)-11 (only highest concen-
trations illustrated) V1/2 (Figure 4B) and k (Figure 4C) values
showed that there were no changes in the steady-state activation
properties of Naþ currents between CAD cells treated with
DMSO control or with any of the tested compounds. These data
indicate that chimeric 1 derivatives do not affect the channel’s
transition from a closed to an open conformation.
Fast Inactivation Properties of Naþ Currents in CAD Cells
Are Affectedby 1Agents.Our data indicated that hybrid agents
(R)-7(R)-11 exhibit profound effects on the slow inactivated
state of Naþ channels. We next asked if these agents could
enhance steady-state fast inactivation. To find out, we used a
protocol (Figure 5A) designed to induce a fast-inactivated state,
as previously described.27 Cells were held at80 mV, stepped to
inactivating prepulse potentials ranging from 120 to 10 mV
(in 10 mV increments) for 500 ms, and then the cells were
stepped to 0 mV for 20 ms to measure the available current. A
500 ms conditioning pulse was used because it allowed all of the
endogenous channels to transition to a fast-inactivated state at all
potentials assayed. Steady-state, fast inactivation curves of Naþ
currents fromDMSO- and all (R)-7(R)-11treated CAD cells
were well fitted with a single Boltzmann function (R2 > 0.9942
for all conditions). The V1/2 value for inactivation for 0.1%
DMSO-treated cells was 63.2 ( 0.9 mV (n = 8), which was
significantly different from that of (R)-7 (30 μM)-treated cells
(84.6 ( 1.2 mV; n = 8; p < 0.05; Student’s t-test; see
Figure 5C). Compared with the ∼21.4 mV shift in V1/2 of fast
inactivation in the hyperpolarizing direction observed in the
presence of (R)-7, the shifts caused by the other 1 agents were as
follows: 19.9 mV, (S)-7 (500 μM; n = 7); 16.8 mV, (R)-8 (100
μM; n = 7); 21.7 mV, (R)-9 (100 μM; n = 7); 17.6 mV, (R)-10
(100 μM; n = 7); and 8.0 mV, (R)-11 (30 μM; n = 7; Figure 5D)
(p < 0.05 vs DMSO control; Student’s t-test). By comparison, we
observed a 0.7 mV shift with (R)-4 (30 μM).27 Additionally, the
time constant for inactivation (τinact) was faster with (R)-7,
compared with DMSO: 0.73( 0.05 ms for 0.3 μM (R)-7 (n = 6)
versus 1.32 ( 0.12 ms for DMSO (n = 6; see Figure 5B, right).
Frequency-Dependent Block of Naþ Currents by 1 Agents
on CAD Cells. We selected (R)-7 and (R)-11 to study the
frequency-dependent block (and development of inhibition/
slow inactivation; see next section) of Naþ currents. (R)-7 and
(R)-11 have comparable structures except their linker units
(Figure 1, sector B) between the two aromatic rings. In (R)-7,
sector B is the oxymethylene unit (OCH2) found in (S)-5, and in
(R)-11 it is a chemical bond. The ability to block Naþ currents in
an activity- or use-dependent manner is a useful property for
antiepileptic drugs, since it allows for preferential decreases in
Naþ channel availability during high- (i.e., seizures) but not low-
frequency firing. Thus, we tested if (R)-7 (8.5 μM) and (R)-11
(15 μM) could elicit use-dependent block. These concentrations
Figure 6. Significant frequency-dependent block by (R)-7 and (R)-11 of Naþ currents in CAD cells. (A) The frequency dependence of block was
examined by holding cells at the hyperpolarized potential of80 mV and evoking currents at 10 Hz by 20 ms test pulses to10 mV. (B) Representative
overlaid traces are illustrated by pulses 1, 10, 20, and 30 for control (predrug) and in the presence of (R)-7 (8.5 μM) and (R)-11 (15 μM). For clarity, the
use dependence traces for (R)-4 and (R)-11 are not shown. (C) Summary of average frequency-dependent decrease in current amplitude ((SEM)
produced by (R)-4 (100 μM), (R)-7, and (R)-11 but not by control conditions. (D) Summary of the maximal decrement in current amplitude observed
at the end of the 30 pulse train for predrug, (R)-4, (R)-7, and (R)-11. (R)-7 and (R)-11 show a significant decrease in current amplitude compared with
pretreatment (/, p < 0.05, one-way ANOVA with Dunnett’s posthoc test). Note the rapid frequency-dependent facilitation of block by both (R)-7 and
(R)-11 that was observed beginning as early as pulse 3 (arrow). Data are from 57 cells per condition.
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were used because they are ∼5-fold above the IC50 values for
slow inactivation for these compounds. A train of 30 test pulses
(20 ms to 10 mV) was delivered from a holding potential
of80mV at 10Hz (Figure 6A). The available current in control
cells and cells in the presence of 1 agents was calculated by
dividing the peak current at any given pulse (pulseN) by the peak
current in response to the initial pulse (pulse1). Both (R)-7 and
(R)-11 reduced current amplitude compared with control
(Figure 6BD). When we tested (R)-4 (100 μM), we also
observed a small level of block, consistent with our previous
findings.27 While use-dependent block by (R)-4 was first
observed by about pulse 19 in the train, (R)-7 and (R)-11 did
not show such latency, with rapid block seen as early as pulse 3
(Figure 6C, arrow). By the last pulse, compared with control, the
peak current was∼9% lower in the presence of (R)-4, 40% lower
in the presence of (R)-7, and 45% lower in the presence of (R)-11
(Figure 6D).
Inhibition/Slow Inactivation Development Rate Is Altered
by (R)-7 and (R)-11 in CADCells.To understand the interaction
between (R)-7 and (R)-11 and Naþ channels, we next investi-
gated the time course of block development by these agents and
compared the results with (R)-4. Block development was exam-
ined by holding the cells at120 mV in the absence or presence
of (R)-4 (100 μM), (R)-7 (8.5 μM), and (R)-11 (15 μM),
prepulsing the cells to 0 mV for varying amounts of time to allow
block to develop, hyperpolarizing the cells to120mV for 20ms
to allow unbound channels to recover from fast inactivation, and
then stepping the cells to 0 mV for 20 ms to determine the
fraction of channels available for activation (Figure 7A). The
reduction in the fraction of current available is indicative of the
time course for the development of slow inactivation. The time
course for reducing channel availability without drug as well as in
the presence of (R)-7 and (R)-11 was biphasic, with a fast
component likely representing block development of fast-inacti-
vated channels and a slow component consistent with the time
course of slow inactivation development (Figure 7B). The time
constant for block development was ∼2-, 4-, and 8-fold faster in
cells treated with (R)-4 (100 μM), (R)-7 (8.5 μM), and (R)-11
(15 μM), respectively, than that with vehicle-treated control
cells. Both (R)-7 and (R)-11 caused reductions in the fraction
of current at 8 s (Figure 7B, inset) compared with control cells
(p < 0.05, one-way ANOVA with Dunnett’s posthoc test).
Inactivation/Block Recovery Is Altered by (R)-7 and (R)-11
in CAD Cells.We also examined the rate at which Naþ channels
in CAD cells recovered from inactivation and/or block by (R)-7
and (R)-11, and the results were compared with (R)-4. Cells
(n = 57 for each condition) were held at120mV, depolarized
to 0 mV for 10 ms, and then hyperpolarized to 120 mV for
variable increasing durations before testing the available current
with a step depolarization to 0 mV (Figure 8A). The time course
of recovery from the 10 ms depolarization was not different from
control for currents recorded in the presence of (R)-4 or (R)-11,
although a slight slowing was observed in the presence of (R)-7
(Figure 8B). In another set of experiments, cells were held
at120mV, depolarized to 0 mV to 5 s, and then hyperpolarized
to 120 mV for a variable duration before testing the available
current with a step depolarization to 0 mV (Figure 8C). The 5 s
depolarization provides sufficient time for the channels to under-
go slow inactivation. The time course for recovery from the 5 s
depolarization was dramatically different from that of control
cells for currents recorded in the presence of (R)-7 and (R)-11
(Figure 8D). The time constant for recovery from the 5 s
prepulse was significantly greater in the presence of either
(R)-7 or (R)-11 (p < 0.01 at 100 ms to 2 s; Figure 8D) and
lesser for (R)-4 (between 100 to 500 ms; p < 0.01; Figure 8D).
1 Agents Do Not Affect Veratridine- or Potassium Chlor-
ide (KCl)-Induced Glutamate Release from Cortical Neurons.
Since glutamate levels are higher in human epileptogenic foci41
and inhibition of glutamate release by antiepileptics such as
phenytoin, carbamazepine, and lamotrigine42 has been reported,
we examined whether inhibition of glutamate release might
contribute to the anticonvulsant properties of any of the novel
1 agents in embryonic cortical neurons. As shown in Figure 9A,
the initial basal or resting release of glutamate was not signifi-
cantly different among any of the conditions. KCl (90 mM)
evoked a significant increase in glutamate release under all
conditions; however, there were no differences in the maximal
glutamate released by KCl from cells treated with DMSO
(control) or with any of the compounds tested (Figure 9A).
The evoked glutamate release (stimulated minus initial basal
release) was also not different for any of the conditions tested
(Figure 9A). The total content of glutamate, measured at the end
of the release experiment, was not different between the control
and any of the drug conditions (p > 0.05, ANOVAwith a Tukey’s
posthoc test; Figure 9B). We also found that veratridine, another
membrane depolarizing agent that acts via activating sodium
channels, did not affect evoked glutamate levels (Table 3).
Notably, veratridine specifically modifies open sodium channels
and requires depolarization for this modification to occur.43
Figure 7. Inhibition/slow inactivation development rate is altered by
(R)-7 and (R)-11 in CAD cells. (A) Voltage protocol for development of
inhibition/slow inactivation. Following a variable conditioning pulse to
0 mV, a 20 ms pulse to120 mV allows recovery from fast inactivation
(but not block) before the fraction of current available with the 20 ms
pulse to 0 mV. (B) (R)-7 and (R)-11 increased the inactivation/
inhibition development rate over that observed in vehicle-treated
CAD cells at prepulse durations greater than 128 ms (p < 0.05, one-
way ANOVA with Dunnett’s posthoc test). Inset: the fraction of current
available at 8 s (arrow) prepulse duration was significantly smaller for
(R)-4 (0.32 ( 0.01, n = 5), (R)-7 (0.20 ( 0.04, n = 8), and (R)-11
(0.12 ( 0.04, n = 8) than for vehicle-treated cells (0.52 ( 0.09, n = 6;
p < 0.05, one-way ANOVA with Dunnett’s posthoc test).
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Another reason why veratridine did not affect Ca2þ release
here is that veratridine itself abolishes inactivation.44 Since
KCl-induced depolarization of glutamate release depends on
Ca2þ influx via high threshold voltage-gated Ca2þ channels,
these results suggest that 1 agents do not target these Ca2þ
channels (see next section).
1 Agents Induce Modest Inhibition of Calcium Influx in
Cortical Neurons. We next wanted to test if chimeric com-
pounds 1 affected depolarization-induced Ca2þ influx in primary
neurons. Changes in intracellular Ca2þwere measured in E18 rat
cortical neurons using the ratiometric Ca2þ-sensitive dye Fura-2.
Ca2þ release was evoked by successive pulses of KCl 5 min apart
(Figure 10A). Exposing cells to (R)-4 (100 μM) prior to the
second KCl pulse resulted in a 9.24 ( 1.66% inhibition of Ca2þ
amplitude compared with 13.74 ( 1.26% inhibition for (S)-4
(Figure 10B). These results are consistent with our recent
electrophysiological study in which we found no effects of
(R)-4 on Ca2þ currents via N- or P/Q-type voltage-gated
calcium channels in hippocampal neurons.45 All 1s, except (S)-7,
showed a modest but significant increase in percent inhibition
compared with (R)-4 (p < 0.05, one-way ANOVA with Dunnett’s
posthoc test). Maximal inhibition of Ca2þ influx (17.3 ( 1.5%)
was observed with (R)-9 (100 μM). However, this is relatively
small compared with 63.3 ( 1.6% inhibition (n = 84) observed
following incubation with Nifedipine (10 μM), a well-established
L-type Ca2þ channel inhibitor. These results suggest that 1s have a
modest effect on depolarization-induced Ca2þ influx.
Neuropathic Pain is Reversed by TreatmentWith (R)-7 but
Not (R)-11.We next examined the effects of (R)-7 and (R)-11 on
established chronic nociceptive behavior in an animal model of
TNI-mediated neuropathic pain.28 TNI induces rapid onset and
prolonged chronic behavioral hypersensitivity to mechanical and
thermal stimuli.28 Here, the ability of (R)-7 and (R)-11 to reverse
tactile hypersensitivity was evaluated in rats at 14 and 28 days
after TNI. Fourteen days following TNI, all animals exhibited
pronounced mechanical allodynia (36.1 ( 3.9 mN; n = 12) in
response to von Frey hair stimulation of the injured hindpaw,
compared with presurgery levels, which averaged 72.7( 3.7 mN
(n = 12). Almost complete (∼90%) reversal of tactile hypersen-
sitivity was observed 1 h after systemic administration of (R)-7
(10 mg/kg, ip) (Figure 11B). In contrast, systemic administra-
tion of (R)-11 (10 mg/kg, ip) was ineffective at reducing
hypersensitivity, with levels averaging 40 ( 4.9 mN (n = 6).
Neither drug administered systemically to control animals had
any effect on paw withdrawal threshold (data not shown).
Mechanical withdrawal threshold changes persisted for all
animals (n = 12) 4 weeks after TNI (Figure 11B). Systemic
administration of (R)-7 (10 mg/kg, ip) partially reversed tactile
hypersensitivity at 1 and 4 h after injection. By 24 h, mechanical
withdrawal thresholds had returned to predrug levels. Both
systemic administration of (R)-11 (10 mg/kg, ip) and morphine
sulfate (10 mg/kg, ip) were ineffective at 28 days. The lack of
effect of morphine in our study is consistent with a previous
report in which neither single doses nor repeated delivery of
morphine had much effect on pain-related behavior due to
spared-nerve injury model.46
Interestingly, we found that 10 mg/kg (R)-7 given ip com-
pletely reversed TNI-induced hypersensitivity while the same
Figure 8. Effects of 1 compounds on Naþ channel inactivation recovery. (A,B) Voltage protocols for recovery of Naþ currents. CAD cells were held
at 120 mV, depolarized to 0 mV for 10 ms or 5 s, and then hyperpolarized to 120 mV for varying increasing durations before testing the available
current with a step depolarization to 0 mV. Data sweeps were acquired at 0.5 Hz for short recovery durations and at slower rates for the longer recovery
durations. (C) (R)-7 (8.5 μM) caused a small decrease in the rate of inactivation/inhibition recovery (10 ms prepulse) for Naþ channels, whereas (R)-4
and (R)-11 had no effect. (D) (R)-4 (100 μM), (R)-7 and (R)-11 (15 μM) slowed recovery kinetics after slow inactivation was induced, compared with
control. In the presence of any of the three compounds, the fraction of available channels after a 5 s depolarization was lower for all three drugs than for
control, and the duration of recovery was longer (significant between 100 ms and 2 s; except for (R)-4where significance was observed between 100 and
512 ms) than that of the control. Numbers in parentheses indicate number of cells patched per condition.
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dose of (R)-11 had no effect. This difference was observed
despite (R)-7 and (R)-11 displaying similar effects on total Naþ
current and VGSC slow inactivation. In contrast, a pronounced
hyperpolarizing shift in voltage-dependent fast inactivation was
observed for 30 μM (R)-7 (21.4 mV in V1/2) compared with a
more modest change for 30 μM (R)-11 (8.0 mV in V1/2). Such a
shift in the voltage-dependence of inactivation could lead to
decreased neuronal excitability, and this decreased excitability of
sensory neurons could be the cause of the antinociceptive effect.
Shifts in fast inactivation have been linked to altered excitability
and VGSC-related pathology. For example, in myopathy char-
acterized by loss of excitability, it is thought that a similar shift in
fast inactivation of muscle VGSC is responsible for muscle fiber
excitability.47,48 Additionally, several mutations in VGSCs asso-
ciated with chronic pain are known to cause depolarizing shifts in
voltage dependence of fast inactivation.49 These studies highlight
how alterations in voltage dependence of fast inactivation can be
important for excitability and VGSC-related pathology. It is not
surprising, then, that VGSC antagonists (e.g., carbamazepine,
lidocaine) have shown efficacy in treating neuropathic pain,
likely, in part, by shifting the V1/2 of fast inactivation.
23,50,51
These findings suggest that (R)-7 may reduce excitability by
shifting the voltage dependence of fast inactivation and thus
abolish TNI-induced hypersensitivity, along with its effect on
sodium channel slow inactivation. An alternative possibility
could be that, like the newly discovered organic compound
Z123212 reported by Snutch and colleagues,52 (R)-7 abolishes
TNI-induced hypersensitivity through a mechanism of enhan-
cing not only Naþ channels but T-type Ca2þ channels as well. It
is also possible that differences in protein-binding of (R)-7 and
(R)-11 as well as the free fractions of (R)-7 and (R)-11 that are
Figure 9. Depolarization-induced glutamate release is not affected by 1
compounds. (A) Bar graph of glutamate release expressed as mean
percent total glutamate content of cells in each well( SEM (n = 4 wells
per condition). Glutamate release was measured from cells treated with
successive incubations of normal nondepolarizing HEPES buffer con-
taining 2.5 mM KCl (basal), depolarizing HEPES buffer containing
90 mM KCl (stimulated), and nondepolarizing HEPES buffer contain-
ing 2.5 mM KCl again. Poststimulation basal release was not more than
5% different from initial basal levels, indicating that exposure to high
extracellular potassium did not damage the cells or induce cell lysis. In all
cases, release stimulated by high extracellular Kþwas significantly higher
than basal release. However, there were no significant differences in
stimulated release between control and any of the drug conditions
(p > 0.05, ANOVA with a Tukey’s posthoc test). (B) Total content of
glutamate was measured at the end of the release experiment. There
were no significant differences in total glutamate content between
control and any of the drug conditions (p > 0.05, ANOVA with a
Tukey’s posthoc test).
Table 3. Veratridine-Induced Glutamate Release Is Not Af-
fected by 1 Compounds
treatment evoked release (% content/15 min)a
control (0.1% DMSO) 45.8( 1.6 (n = 6)
(R)-4b 46.7( 4.7 (n = 5)
(R)-7 45.7( 0.6 (n = 6)
(S)-7 50.0( 0.5 (n = 5)
(R)-8 48.9( 0.6 (n = 5)
(R)-9 43.6( 1.9 (n = 5)
(R)-10 47.6( 7.7 (n = 5)
(R)-11 58.0 ( 1.0 (n = 6)
a Evoked release, the difference between veratridine-stimulated minus
initial basal releases, was normalized to the total content of glutamate
over a 15min period. The total content of glutamate wasmeasured at the
end of the release experiment. There were no significant differences in
evoked release between control and any of the drug conditions (p > 0.05,
ANOVA with a Tukey’s post hoc test). b 100 μM of (R)-4 or 1 agents
was separately added to neurons 30 min prior to the initial basal and
maintained throughout the basal (10 min) and stimulated (15 min)
measurements.
Figure 10. Modest inhibition of depolarization-induced Ca2þ influx by
1 compounds in cortical neurons. (A) Ca2þ imaging was performed on
E18 rat cortical neurons using the ratiometric Ca2þ-sensitive dye Fura-2.
Following a 1 min baseline measurement, neurons were stimulated with
46.5 mM KCl for 3040 s to induce Ca2þ influx. Neurons were gently
washed and then treated singly with drugs (1% DMSO or 100 μM
compound) for 5 min before stimulating again with 46.5 mM KCl.
Representative traces from the indicated treatment groups are shown.
(B) Bar graph shows the percent inhibition (adjusted for nonspecific
inhibition by DMSO) for the 1 compounds. Values represent the
average ( SEM from two separate imaging experiments, with the
number of cells per condition indicated in parentheses. Asterisks (/)
indicate statistical significance compared with (R)-4 by one-way
ANOVA followed by Dunnett’s posthoc test p < 0.05. RFU = relative
fluorescence units.
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available for pharmacological actions may account for their
differential effects on TNI.
The results from the TNI model for (R)-7 and (R)-11 were
compared with findings from the mouse (ip) formalin-induced
pain model, conducted at the NINDS ASP (data not shown).
(R)-7 showed potent protection against chronic (late-phase)
inflammatory pain (15 mg/kg: 44% protection vs control), while
(R)-11 displayed no detectable protection (12 mg/kg: 97%
protection vs control). In this test protocol, the lower the
observed percent protection versus control, the more effective
the compound is in preventing neuropathic pain. Recently,
Vissers and co-workers demonstrated a good correlation be-
tween findings in the chronic phase of the formalin test and
results for cold allodynia in the chronic constriction injury model
for rats (r = 0.72) and gerbils (r = 0.68) using drugs with proven
pain-attenuating effects in humans.53
’CONCLUSIONS
Chimeric agents 1 were formed by merging the structures of
functionalized amino acids (2) and R-amino acid amides (3)
with the expectation that the new compounds would retain
pharmacological properties observed for both 2 and 3. This
appears to be the case. Chimeric 1 showed excellent anti-
convulsant activities in seizure models comparable with and in
some cases exceeding (R)-4 and (S)-5 ((S)-6). When we
examined 1 activities on sodium channel function by whole-cell
patch-clamp electrophysiology using CAD cells, we observed
that that they were uniformly more potent (1653-fold) than
(R)-4 in facilitating slow inactivation (Table 1). Interestingly, we
found a marked increase in state-dependent block and an
increase in the level of fast inactivation accompanied the change.
Notably, (R)-4 showed preferential inactivation of slow
inactivation,22 and (S)-513,24and (S)-615 both modulated fast
inactivation. The extent of fast inactivation depended on the 40
structural unit in the chimeric 1 agents. For (R)-7, into which we
placed a (300-fluorophenmethyl)oxy unit at the 40 position, we
observed a significant increase in fast inactivation compared with
(R)-11, into which we placed a 300-fluorophenyl moiety. While
the structural moiety at the 40 position did not appreciably affect
the slow inactivation properties of the chimeric 1s or their
anticonvulsant activities, they did dramatically influence their
antinociceptive properties in the rat-TNI model. Administration
of (R)-7 led to complete reversal of evoked pain, while (R)-11
had no detectable effect. Future studies will explore the possible
role of the dual promotion of slow and fast sodium channel
inactivation processes for novel chimeric 1 agents in this and
related neuropathic pain models.
’METHODS
Chemistry. Preparation of 4-((20-Fluorophenoxy)methyl)ben-
zonitrile (14). A mixture of 12 (25.00 g, 127.5 mmol), K2CO3
(425.20 g, 400.0 mmol), and 13 (11.90 g, 106.3 mmol) was heated
at reflux in acetone (400 mL) (4 h). The volatiles were evaporated,
and the residue was diluted with CH2Cl2 (300 mL). The organic layer
was washed with H2O (300 mL), dried (MgSO4), and concentrated
in vacuo to give white needles (19.21 g, 86%): Rf = 0.28 (hexanes/
ethyl acetate 9/1); mp 6970 C; 1H NMR (CDCl3) δ 5.19
(s, CH2O), 6.917.14 (m, 2 ArH), 7.017.14 (m, 2 ArH), 7.56
(d, J = 7.8 Hz, 2 ArH), 7.67 (d, J = 7.8 Hz, 2 ArH); 13C NMR (CDCl3)
δ 70.3 (CH2O), 111.8 (CCN), 115.8 (C60), 116.5 (d, J = 18.6 Hz,
C30), 118.6 (CN), 122.2 (d, J = 6.9 Hz, C50 or C40), 124.3 (d, J =
3.8 Hz, C50 or C40), 127.5, 132.4, 142.0 (3Ar), 146.2 (d, J = 10.9 Hz,
C10), 152.9 (d, J = 244.7 Hz, C20); HRMS (M þ Hþ) (ESIþ) not
observed [M þ Hþ] (calcd for C14H10FNOHþ 228.0825).
Preparation of 4-((20-Fluorophenoxy)methyl)benzylamine (15).
To a LiAlH4 (4.75 g, 198.2 mmol) suspension in tetrahydrofuran
(THF; 600 mL) was added dropwise at 0 C a THF (30 mL) solution
of 14 (15.00 g, 66.1 mmol). The mixture was stirred at room tempera-
ture (16 h). Then, H2O (6 mL) was added dropwise at 0 C followed by
an aqueous NaOH solution (3 mL, 15% w/w) and H2O (6 mL). The
mixture was stirred at room temperature (2 h), and the precipitate was
filtered and the pad was washed with CH2Cl2. The filtrate was
concentrated in vacuo to obtain 11.20 g (73%) of 15 as a colorless oil:
Rf = 0.00 (hexanes/EtOAc 9/1);
1HNMR (CDCl3) δ 1.65 (br s, NH2),
Figure 11. (R)-7, but not (R)-11, reverses mechanical hypersensitivity in the TNI model of neuropathic pain. (A) Diagram of the sural, tibial, and
common peroneal terminal nerve branches of the sciatic nerve and their dorsal root origins. Neuropathic pain was induced by ligation of the tibial nerve
and 24 mm of the nerve distal to the ligation was removed. (B) Withdrawal threshold (in milli-Newtons, mN) in response to von Frey stimulation to
the paw ipsilateral to TNI following a single, intraperitoneal administration of (R)-7 or (R)-11 (10 mg/kg, n = 6) at 2 and 4 weeks after injury. A single
injection of (R)-7 almost completely reversed TNI-induced mechanical hypersensitivity (p < 0.05; Student’s t-test) compared with injured animals that
did not receive (R)-7. At 4 weeks, the ability of (R)-7 to reverse TNI-induced mechanical hypersensitivity was diminished but remained significantly
different from vehicle control animals. Neither (R)-11 at 2 and 4 weeks after injury or morphine (10 mg/kg) administered at 4 weeks changed the TNI
induced pain behavior.
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3.86 (s, CH2NH2), 5.11 (s, CH2O), 6.857.20 (m, 4 ArH), 7.31 (d, J =
8.0 Hz, 2 ArH), 7.40 (d, J = 8.0 Hz, 2 ArH); 13C NMR (CDCl3) δ 46.2
(CH2NH3), 71.2 (CH2O), 115.8 (d, J = 2.3 Hz, C60), 116.9 (d, J = 17.8
Hz, C30), 121.5 (d, J = 6.2 Hz, C50 or C40), 124.2 (d, J = 4.6 Hz, C50 or
C40), 127.7, 127.8, 135.9, 137.7 (4 Ar), 146.6 (d, J = 10.8 Hz,C10), 152.9
(d, J = 244.7 Hz, C20); HRMS (M þ Hþ) (ESIþ) 232.1138
[M þ Hþ] (calcd for C14H14FNOHþ 232.1137).
Preparation of (R)-N-40-((20 0-Fluorophenoxy)methyl)benzyl
2-N-(tert-butoxycarbonyl)amino-3-hydroxypropionamide ((R)-17).
A THF solution (250 mL) of (R)-16 (5.00 g, 21.6 mmol) was stirred
and cooled at78 C under Ar, and then 4-methylmorpholine (NMM)
(2.9 mL, 26.0 mmol) was added dropwise. After 2 min of stirring at this
temperature, isobutylchloroformate (IBCF) (3.4 mL, 26.0 mmol) was
added dropwise leading to the precipitation of a white solid, and the
reaction was allowed to proceed for additional 2 min, and then 15 (6.00
g, 26.0 mmol) was added portionwise at 78 C. The mixture was
allowed to stir at room temperature (2 h), and the white solid filtered
and the organic layer concentrated in vacuo. The residue was purified by
flash column chromatography on silica gel with EtOAc/hexanes (5/5 to
8/0) as the eluant to obtain (R)-17 as a white solid (8.10 g, 90%):
Rf = 0.36 (hexanes/EtOAc 5/5); mp 6467 C; [R]25.2D þ31.2
(c 0.5, CHCl3); IR (crystal) 3327, 3003, 2943, 1734, 1686, 1651,
1557, 1522, 1508, 1454, 1445, 1366, 1261, 1229, 1217, 1206, 1165,
1109, 1034, 1007, 792 cm1; 1H NMR (400 MHz, CDCl3) δ 1.41
(s, (CH3)3), 3.153.42 (br m, OH), 3.613.73 (br m, CHH0),
4.024.21 (br m, CHH0, CH), 4.304.58 (br m, CH2NH), 5.09 (s,
OCH2), 5.545.68 (br t, NH), 6.877.16 (m, 4 ArH, NH), 7.247.29
(m, 2 ArH), 7.367.40 (m, 2 ArH); 13C NMR (100 MHz, CDCl3) δ
28.2 ((CH3)3), 43.1 (NCH2), 54.8 (OCH2CH), 62.8 (OCH2CH), 71.0
(OCH2), 80.6 (C(CH3)3), 115.7 (C60), 116.3 (d, J = 17.8 Hz, C30),
121.4 (d, J = 6.9 Hz, C50or C40), 124.2 (d, J = 3.9 Hz, C50or C40), 127.3,
127.7, 135.1, 143.2 (4 Ar), 146.7 (d, J = 10.8 Hz,C10), 153.0 (d, J = 243.9
Hz, C20), 156.3 (NHC(O)O), 171.4 (C(O)); HRMS (M þ Naþ)
(ESIþ) 441.1802 [M þ Naþ] (calcd for C22H28N2O5Naþ 442.1874).
Anal. Calcd. for C22H28FN2O5: C, 63.14; H, 6.50; F, 4.54; N, 6.69.
Found: C, 62.86; H, 6.57; F, 4.34; N, 6.88.
Preparation of (R)-N-40-((20 0-Fluorophenoxy)methyl)benzyl
2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide ((R)-18).
Ag2O (20.44 g, 88.5 mmol) was added to a CH3CN solution
(450 mL) of (R)-17 (7.40 g, 17.7 mmol) and CH3I (11.0 mL, 177.0
mmol) at room temperature under Ar. The reaction mixture was stirred
at room temperature in the dark (3 d) and filtered through Celite, and
the filtrate concentrated in vacuo to obtain a white solid. The solid was
purified by flash column chromatography on silica gel with EtOAc/
hexanes (3/7 to 6/4) as the eluant to obtain (R)-18 as a white solid (5.00
g, 65%): Rf = 0.61 (EtOAc/hexanes 1/1); mp 103104 C; [R]25.9D
16.5 (c 0.5, CHCl3); IR (crystal) 3370, 1695, 1682, 1647, 1547, 1524,
1504, 1460, 1391, 1364, 1317, 1277, 1254, 1198, 1167, 1109, 1086, 1045,
1018, 1001 cm1; 1H NMR (400 MHz, CDCl3) δ 1.43 (s, (CH3)3C),
3.37 (s, CH3), 3.483.51 (br m, CHH0), 3.84 (dd, J = 3.2, 5.6 Hz,
CHH0), 4.224.29 (m, CH), 4.414.53 (m, CH2NH), 5.12 (s, OCH2),
5.325.44 (br m, NH), 6.686.76 (br m, NH), 6.897.14 (m, 4 ArH),
7.28 (d, J = 8.2 Hz, 2 ArH), 7.40 (d, J = 8.2 Hz, 2 ArH); 13C NMR (100
MHz, CDCl3) δ 28.2 ((CH3)3), 43.1 (NCH2), 54.0 (OCH2CH), 56.1
(OCH3), 71.0, 72.0 (2 OCH2), 80.5 (C(CH3)3), 115.7 (d, J = 1.6 Hz,
C60), 116.3 (d, J = 17.8 Hz, C30), 121.5 (d, J = 7.0 Hz, C50or C40), 124.2
(d, J = 3.9 Hz, C50or C40), 127.7, 127.8, 135.8, 137.9 (4 ArH), 146.6 (d,
J = 10.8Hz,C10), 152.9 (d, J = 244.7Hz,C20), 155.5 (NHC(O)O), 170.3
(C(O)); HRMS (M þ Naþ) (ESIþ) 455.1958 [M þ Naþ] (calcd for
C23H29FN2O5Na
þ 455.1952). Anal. Calcd. for C23H29FN2O5: C,
63.87; H, 6.76; F, 4.39; N, 6.48. Found: C, 64.01; H, 6.85; F, 4.31;
N, 6.56.
Preparation of (R)-N-40-((200-Fluorophenoxy)methyl)benzyl 2-acet-
amido-3-methoxypropionamide ((R)-10). A saturated HCl solution in
dioxane (1 mmol/2 mL, 22.2 mL) was added to an Et2O (10 mL)
solution of (R)-18 (4.50 g, 11.1 mmol) at 0 C, and the solution was
stirred at room temperature (16 h). The reaction solution was concen-
trated in vacuo and dried (30 min).
The residue was dissolved in CH2Cl2 (60 mL), and Et3N (4.7 mL,
33.3 mmol) and AcCl (1.2 mL, 16.7 mmol) were successively added at
0 C. The mixture was stirred at room temperature (16 h), aqueous 10%
citric acid (60 mL) was added, and then the organic layer was separated.
The aqueous layer was washed with CH2Cl2 (2  30 mL). All of the
organic layers were combined, washed with aqueous saturated NaHCO3
(30 mL) and H2O (30 mL), dried (MgSO4), and concentrated in vacuo.
The solid was recrystallized with EtOAc to obtain (R)-10 as a white solid
(2.40 g, 58%): Rf = 0.31 (EtOAc); mp 149 C; [R]25.3D 20.2
(c 0.5, CHCl3); IR (crystal) 3281, 1645, 1549, 1506, 1456, 1433,
1375, 1312, 1281, 1261, 1231, 1198, 1111, 1097, 1040, 1001,
989 cm1; 1H NMR (400 MHz, CDCl3) δ 2.03 (s, CH3C(O)), 3.37
(s, CH3), 3.403.45 (br m, CHH0), 3.803.83 (m, CHH0), 4.464.54
(m, CH, CH2NH), 5.12 (s, OCH2), 6.40 (br d, J = 4.8 Hz, NH),
6.716.78 (br m, NH), 6.907.14 (m, 4 ArH), 7.27 (d, J = 6.8 Hz,
2 ArH), 7.41 (d, J = 6.8Hz, 2 ArH), addition of excess (R)-()-mandelic
acid to a CDCl3 solution of (R)-10 gave only one signal for the acetyl
methyl and one signal for the ether methyl protons; 13C NMR (100
MHz, CDCl3) δ 28.2 (CH3(O)), 43.2 (NCH2), 52.4 (OCH2CH), 59.1
(OCH3), 71.0, 71.7 (2 OCH2), 115.7 (d, J = 1.5 Hz, C60), 116.3 (d, J =
18.6Hz,C30), 121.5 (d, J= 7.0Hz,C50 orC40), 124.2 (d, J = 3.9Hz,C50 or
C40), 127.7, 127.8, 135.9, 137.8 (4 Ar), 146.6 (d, J = 10.1 Hz,C10), 152.9
(d, J = 244.7 Hz, C20), 170.0, 170.3 (2 C(O)); HRMS (M þ Naþ)
(ESIþ) 397.1540 [MþNaþ] (calcd for C20H23FN2O4Naþ 397.1534).
Anal. Calcd. for C20H23FN2O4: C, 64.16; H, 6.19; F, 5.07; N, 7.48.
Found: C, 64.01; H, 6.14; F, 4.91; N, 7.55.
Electrophysiology. Whole-cell voltage clamp recordings were
performed at room temperature onCAD cells using an EPC 10 amplifier
(HEKA Electronics, Germany). Electrodes were pulled from thin-walled
borosilicate glass capillaries (Warner Instruments, Hamden, CT) with a
P-97 electrode puller (Sutter Instrument, Novato, CA) such that final
electrode resistances were 12 MΩ when filled with internal solutions.
The internal solution for recording Naþ currents contained (in mM)
110 CsCl, 5 MgSO4, 10 EGTA, 4 ATP Na2-ATP, and 25 HEPES
(pH 7.2, 290310mOsm/L). The external solution contained (inmM)
100 NaCl, 10 tetraethylammonium chloride (TEA-Cl), 1 CaCl2,
1 CdCl2, 1 MgCl2, 10 D-glucose, 4 4-AP, 0.1 NiCl2, and 10 HEPES
(pH 7.3, 310315 mOsm/L). Whole-cell capacitance and series
resistance were compensated with the amplifier. Series resistance error
was always compensated to be less than(3mV.Cells were considered only
when the seal resistance was less than 3 MΩ. Linear leak currents were
digitally subtracted by P/4. To negate any potential effects of time-
dependent shifts in the voltage dependence of fast inactivation, we
compareddata obtained34min after establishing thewhole-cell recording
configuration from cells without drug against cells with the 1 agents.
Data Acquisition and Analysis. Signals were filtered at 10 kHz
and digitized at 1020 kHz. Analysis was performed using Fitmaster and
origin8.1 (OriginLab Corporation, Northampton, MA). For activation
curves, conductance (G) through Naþ channels was calculated using the
equation G = I/(Vm  Vrev), where Vrev is the reversal potential, Vm is
the membrane potential at which the current was recorded, and I is the
peak current. Activation and inactivation curves were fitted to a single-
phase Boltzmann function G/Gmax = 1/{1þexp[(V  V50)/k]}, where
G is the peak conductance, Gmax is the fitted maximal G, V50 is the half-
activation voltage, and k is the slope factor. Additional details of specific
pulse protocols are described in the results text or figure legends.
Potassium Chloride- or Veratridine-Induced Glutamate
Release. Glutamate released from embryonic cortical neurons was
measured using the Amplex Red glutamic acid/glutamate oxidase assay
kit (Invitrogen) as described previously.54,55 In this assay, L-glutamic
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acid is oxidized by glutamate oxidase to produce R-ketoglutarate, NH3,
and H2O2. H2O2 reacts with the Amplex Red reagent in a 1:1 stoi-
chiometry in a reaction catalyzed by horseradish peroxidase (HRP) to
generate the highly fluorescent product resorufin. After 30 min, fluor-
escence of resorufin was measured in a Victor3 V multilabel plate reader
(Perkin-Elmer, Shelton, CT) using excitation at 530 nm and emission
at 590 nm.
To generate samples, neurons growing in 12-well plates were washed
three times (300 μL each) with nondepolarizing buffer (119 mMNaCl,
2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES, and 30 mM
D-glucose). A 100 μL sample was collected after the third wash for basal
samples. After a 15 min stimulation with depolarizing buffer (32 mM
NaCl, 90 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES, and
30 mM D-glucose), 100 μL of culture supernatant was collected and
stored at 20 C. Finally, neurons were bathed in nondepolarizing
buffer for 15 min to re-establish resting levels. For veratridine release
experiments, 100 μM veratridine was used as the stimulus in nondepo-
larizing buffer. Then 100 μM of (R)-4 or 1 agents was separately added
to neurons 30 min prior to the initial basal and maintained throughout
the basal (10 min) and stimulated (10 min) measurements. The
nontransportable glutamate transporter inhibitor DL-threo-β-benzylox-
yaspartate (DL-TBOA; 500 μM) was present during the stimulation to
prevent reuptake of released glutamate.55 The remaining glutamate
content in each well was determined by exposing the cells to 2% Triton
X-100 in nondepolarizing buffer. Total content levels represent the sum
of the remaining glutamate content with the previously collected
fractions. The glutamate released during the 15 min stimulation period
is expressed as percent of the total content. Standard curves for the assay
with known concentrations of exogenous glutamate demonstrated high
reproducibility and sensitivity of the assay, with a lower limit of detection
of∼15 fmol glutamate. Standard curves were constructed for each assay.
The concentrations of Kþ and time period for stimulation were chosen
because they lie on the middle of the sloped portion of the concentration
response curve for KCl-stimulated glutamate release. In additional
control experiments, the general Ca2þ channel blocker CdCl2 (500 μM)
blocked basal and Kþ-stimulated glutamate release (not shown).
Fluorescent Calcium Imaging.Changes in internal calciumwere
monitored using the Ca2þ sensitive dye Fura-2AM (Invitrogen, Carlsbad,
CA). E18 neurons grown in culture for four days were loaded with 3 μM
Fura-2AM (in nondepolarizing Hepes buffer; 119 NaCl, 2.5 KCl,
2 CaCl2, 2 MgCl2, 25 HEPES pH 7.5, 30 glucose, concentrations
in mM) for 25 min at room temperature protected from light. Neurons
were then washed thrice with buffer and transferred to the imaging stage.
Neurons loaded with the cell permeable Fura-2AM were visualized by
differential interference contrast at 20 for a field of view containing
∼70 neurons. After a 1 min baseline of ratiometric fluorescent units
(RFUs) was obtained, neurons were stimulated with 46.5 mM KCl for
3040 s and then washed in normal nondepolarizing Hepes buffer,
which allowed a return to baseline RFUs. Cell fluorescence was
measured by digital video microfluorometry with an intensified CCD
camera coupled to a microscope and Nikon Elements software (Nikon
Instruments Inc., Melville, NY). Cells were illuminated with a Lamda
DG-4 175 W xenon lamp, and the excitation wavelengths of Fura-2
(340/380 nm) were selected by a filter changer. Fura-2 fluorescence
(F340/F380) was measured every 10 s to minimize photobleaching. After
a baseline of at least six images was obtained, neurons were stimulated
by exposure to 46.5 mM KCl (peak 1, P1) for 3040 s, leading to a
sharp increase in F340/F380 which returned to baseline levels when KCl
was removed. Neurons were then treated for 5 min with vehicle or drug
prior to being stimulated again with 46.5 mM KCl (peak 2, P2) as
before. Only cells that displayed a P1 ratio that was 2-fold greater than
baseline were used to determine the inhibitory effect of the drugs. After
subtracting baseline values, inhibition was calculated using the follow-
ing equation % inhibition = 100  [(P2  P1)/P1].
Tibial-Nerve Injury. All procedures were performed on adult
(150200 g) female SpragueDawley rats. The experiments were
approved by the Animal Care Committee of the Indiana University
School of Medicine and followed IASP ethical guidelines.
Under isoflurane (2%) anesthesia, the skin on the lateral surface of the
thigh was incised and a section made directly through the biceps femoris
muscle exposing the sciatic nerve and its three terminal branches: the
sural, common peroneal and tibial nerves. The surgical procedure
comprised an axotomy and ligation of the tibial nerve leaving the
common peroneal and sural nerves intact. The tibial nerve was tightly
ligated with 5.0 silk and sectioned distal to the ligation, removing 24
mm of the distal nerve stump (Figure 11A). Effort was made to avoid
contact with or stretching of the intact common peroneal and sural
nerves. Muscle and skin were closed in two layers. Sham controls
involved exposure of the sciatic nerve and its branches without any
lesion.
Behavior: Foot Withdrawal to Punctate Mechanical In-
dentation. Sixteen animals were divided into two groups: twelve
animals with a tibial nerve injury and four sham control animals. The
animals were tested for behavioral responsiveness after 3 days of
habituation to the testing environment and observer. Behavioral baseline
measurements were collected from at least 2 separate days prior to the
surgery. The rats were then tested 7 days after the surgery and weekly
thereafter.
The incidence of foot withdrawal was measured in response to
mechanical indentation of the plantar surface of each hind paw with
custom Von Frey-type filaments. Mechanical stimuli were applied with
seven filaments, each differing in the bending force delivered (10, 20, 40,
60, 80, 100, and 120 mN), but each fitted with the same metal cylinder
with a flat tip and a fixed diameter of 0.2 mm. The filaments will be
applied in order of ascending force. Each filament was applied to the foot
ipsilateral to the nerve injury. The duration of each stimulus was
approximately 1 s followed by an interstimulus interval of approximately
1015 s. The incidence of foot withdrawal was expressed as a
percentage of the six applications of each stimulus and the percentage
of withdrawals was then plotted as a function of force. The von Frey
withdrawal threshold was defined as the force that evoked a minimum
detectable withdrawal observed on 50% of the tests given at the same
force level. For cases in which none of the specific filaments used evoked
withdrawals on exactly 50% of the tests, linear interpolation will be used
to define the threshold.
The incidence of foot withdrawal was expressed as a percentage of the
six applications of each filament as a function of force. A Hill equation
was fitted to the function (Origin version 6.0, Microcal Software,
Northampton MA) relating the percentage of indentations eliciting a
withdrawal to the force of indentation. From this equation, the paw
withdrawal threshold (PWT) force was obtained and defined as the
force corresponding to a 50% withdrawal. In each behavioral testing
sequence, the operator was blinded to the animal treatment condition.
Drugs and Drug Administration. Morphine sulfate salt was
provided from NIDA Drug Supply Program (Rockville, MD). Systemic
morphine or vehicle was administered by intraperitoneal injection in a
volume of 250 μL. (R)-7 and (R)-11 were employed in this model. Both
compounds were freshly prepared in saline (0.5% DMSO) on the day of
the experiment (10 mg/kg). (R)-7 (n = 6) and (R)-11 (n = 6) were
administered as a one-time intraperitoneal (ip) injection 1 h prior
to behavioral testing. Sham control animals also were treated with
10 mg/kg dose of (R)-7 (n = 2) and (R)-11 (n = 2).
Animals were randomly assigned to the two drug treatment groups.
Results are presented as mean( SEM. The data were analyzed by one-
way ANOVA and Bonferroni posthoc tests. A p value of <0.05 was
accepted as significant.
Statistical Analyses. Differences between means were compared
by either paired or unpaired, two-tailed Student’s t-tests or an analysis of
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variance (ANOVA) when comparing multiple groups (repeated mea-
sures whenever possible). If a significant difference was determined by
ANOVA, then a Dunnett’s or Tukey’s posthoc test was performed. Data




*E-mail: khanna5@iupui.edu (R.K.); harold_kohn@email.unc.
edu (H.K.).
Author Contributions
#These authors contributed equally to the work.
Author Contributions
Y.W. conducted whole cell electrophysiology. S.W. performed
glutamate release experiments and helped in the editing of the
manuscript. J.M.B. performed the calcium imaging experiments.
M.S.R. performed the tibial-nerve injury and behavior experi-
ments. C.S. and K.D.P. synthesized the compounds. F.A.W.
analyzed the behavior data and helped write the injury and
behavior sections. R.K. and H.K. conceived the study, designed
and supervised the overall project, and wrote the manuscript.
Funding Sources
This work is supported by grants from the National Institutes of
Health (NIH) (R01NS054112 to H.K.; NS049136 and
DA026040 to F.A.W.), Award UL1RR025747 from the National
Center for Research Resources (H.K.), the Indiana State Depart-
ment of HealthSpinal Cord and Brain Injury Fund (A70-
9-079138 to R.K.), the Indiana University Biomedical Commit-
teeResearch Support Funds (2286501 to R.K.), and the Elwert
Award in Medicine to R.K. The work performed at NIMH was
supported by NIMH Psychoactive Drug Screening Program,
Contract No. HHSN-271-2008-00025-C (NIMH-PDSP). S.M.
W. is a Stark Scholar. J.M.B. is the recipient of a Larry Kays
Medical Neuroscience fellowship.
’DISCLOSURE
The content is solely the responsibility of the authors and does
not represent the official views of the National Center for
Research Resources, National Institute of Neurological Disor-
ders and Stroke, or the National Institutes of Health.
Notes
H.K. has a royalty-stake position in (R)-4, and UNC has filed
patent applications in behalf of the compounds in this study.
’ACKNOWLEDGMENT
We thank Dr. Theodore Cummins (SNRI, Indiana University
School of Medicine) and Andrew Piekarz for discussions and
comments on themanuscript.We thank theNINDS and the ASP
at theNational Institutes ofHealth with James P. Stables andDrs.
Tracy Chen and Jeffrey Jiang for kindly performing the pharma-
cological studies via the ASP’s contract site at the University of
Utah with Drs. H. Wolfe, H. S. White, and K. Wilcox. We express
our appreciation to Dr. Bryan L. Roth and Mr. Jon Evans at the
National Institute of Mental Health (NIMH) Psychoactive Drug
Screening Project for performing in vitro receptor binding
studies. The NIMH PDSP is directed by Bryan Roth M.D., Ph.
D. at the University of North Carolina at Chapel Hill and Project
Officer Jamie Driscol at NIMH, Bethesda, MD.
’ABBREVIATIONS
FAA, functionalized amino acid; AAA, R-amino acid amide;
AED, antiepileptic drug; TTX-S, tetrodotoxin-sensitive; TNI,
tibial-nerve injury; VGSC, voltage-gated Naþ channel; CAD,
catecholamine A differentiated; SAR, structureactivity relation-
ship; NaV1.x, voltage-gated Na
þ channel isoform 1.x; INa,
Naþ current;MES, maximal electroshock; ASP, Anticonvulsant
Screening Program;NINDS, National Institute of Neurological
Disorders and Stroke; ip, intraperitoneally; po, orally; ED50, 50%
effective dose; TD50, 50% neurological impairment; scMet, sub-
cutaneous Metrazol; CNS, central nervous system; IC50, concen-
tration at which half of the channels have transitioned to a slow
inactivated state;NIMH, National Institute of Mental Health
’REFERENCES
(1) Salome, C., Salome -Grosjean, E., Stables, J. P., and Kohn, H.
(2010) Merging the structural motifs of functionalized amino acids and
R-aminoamides: Compounds with significant anticonvulsant activities.
J. Med. Chem. 53, 3756–3771.
(2) Cortes, S., Liao, Z.-K, Watson, D., and Kohn, H. (1985) Effect of
structural modification of the hydantoin ring on anticonvulsant activity.
J. Med. Chem. 28, 601–606.
(3) Conley, J. D., and Kohn, H. (1987) Functionalized D,L-amino
acid derivatives. Potent new agents for the treatment to epilepsy. J. Med.
Chem. 30, 567–574.
(4) Kohn, H., and Conley, J. D. (1988) New antiepileptic agents.
Chem. Br. 24, 231–234.
(5) Kohn, H., Conley, J. D., and Leander, J. D. (1988) Marked
stereospecificity in a new class of anticonvulsants. Brain Res. 457,
371–375.
(6) Kohn, H., Sawhney, K. N., LeGall, P., Conley, J. D., Robertson,
D. W., and Leander, J. D. (1990) Preparation and anticonvulsant activity
of a series of functionalized R-aromatic and R-heteroaromatic amino
acids. J. Med. Chem. 33, 919–926.
(7) Kohn, H., Sawhney, K. N., LeGall, P., Robertson, D. W., and
Leander, J. D. (1991) Preparation and anticonvulsant activity of a series
of functionalized R-heteroatom-substituted amino acids. J. Med. Chem.
34, 2444–2452.
(8) Kohn, H., Sawhney, K. N., Bardel, P., Robertson, D. W., and
Leander, J. D. (1993) Synthesis and anticonvulsant activities of
R-heterocyclic R-acetamido-N-benzylacetamide derivatives. J. Med.
Chem. 36, 3350–3360.
(9) Bardel, P., Bolanos, A., and Kohn, H. (1994) Synthesis and
anticonvulsant activities of R-acetamido-N-benzylacetamide derivatives
containing an electron-deficient R-heteroaromatic substituent. J. Med.
Chem. 37, 4567–4571.
(10) Choi, D., Stables, J. P., and Kohn, H. (1996) Synthesis and
anticonvulsant activities of N-benzyl-2-acetamidopropionamide deriva-
tives. J. Med. Chem. 39, 1907–1916.
(11) Pevarello, P., Bonsignori, A., Dostert, P., Heidempergher, F.,
Pinciroli, V., Colombo, M., McArthur, R. A., Salvati, P., Post, C., Fariello,
R. G., and Varasi, M. (1998) Synthesis and anticonvulsant activity of a
new class of 2-[(arylalkyl)amino]alkanamide derivatives. J. Med. Chem.
41, 579–590.
(12) Caccia, C., Maj, R., Calabresi, M., Maestroni, S., Faravelli, L.,
Curatolo, L., Salvati, P., and Fariello, R. G. (2006) Safinamide: From
molecular targets to a new anti-Parkinson drug. Neurology 67 (7, Suppl.
2), S18–S23.
(13) Salvati, P., Maj, R., Caccia, C., Cervini, M. A., Fornaretto, M. G.,
Lamberti, E., Pevarello, P., Skeen, G. A., White, H. S., Wolf, H. H.,
Faravelli, L., Mazzanti, M., Mancinelli, M., Varasi, M., and Fariello, R. G.
(1999) Biochemical and electrophysiological studies on the mechanism
331 dx.doi.org/10.1021/cn200024z |ACS Chem. Neurosci. 2011, 2, 317–332
ACS Chemical Neuroscience RESEARCH ARTICLE
of action of PNU-151774E, a novel antiepileptic compound.
J. Pharmacol. Exp. Ther. 288, 1151–1159.
(14) Vereroni, O., Maj, R., Calabresi, M., Faravelli, L., Fariello, R. G.,
and Salvati, P. (2003) Anti-alloodynic effect of NW-1029, a novel Naþ
channel blocker, in experimental animal models of inflammatory and
neuropathic pain. Pain 102, 17–25.
(15) Stummann, T. C., Salvati, P., Fariello, R. G., and Faravelli, L.
(2005) The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-
resistant and tetrodotoxin-sensitive Naþ currents in dorsal root ganglion
neurons. Eur. J. Pharmacol. 510, 197–208.
(16) Perucca, E., Yasothan, U., Clincke, G., and Kirkpatrick, P.





(19) Stoehr, T., Kupferberg, H. J., Stables, J. P., Choi, D., Harris,
R. H., Kohn, H., Walton, N., and White, H. S. (2007) Lacosamide, a
novel anti-convulsant drug, shows efficacy with a wide safety margin in
rodent models for epilepsy. Epilepsy Res. 74, 147–154.
(20) Maj, R., Fariello, R., Pevarello, P., Varasi, M., McArthur, R. A.,
and Salvati, P. (1999) Anticonvulsant activity of PNU-151774E in the
amygdala kindled model of complex partial seizures. Epilepsia 40,
1523–1528.
(21) Levy, R. H.; Mattson, R.; Meldrum, B. (1995) Antiepileptic
Drugs, 4th ed., Chapter 6, Raven Press, New York.
(22) Errington, A. C., Stoehr, T., Heers, C., and Lees, G. (2008) The
investigational anticonvulsant lacosamide selectively enhances slow
inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73,
157–169.
(23) Sheets, P. L., Heers, C., Stoehr, T., and Cummis, T. R. (2008)
Differential block of sensory neuronal voltage-gated sodium channels by
lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide],
lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 326, 89–99.
(24) Fariello, R. G. (2007) Safinamide. Neurotherapeutics 4, 110–116.
(25) Porter, R. J., Cereghino, J. J., Gladding, G. D., Hessie, B. J.,
Kupferberg, H. J., Scoville, B., and White, B. G. (1984) Antiepileptic
drug development program. Cleveland Clin. Q. 51, 293–305.
(26) Wang, H., and Oxford, G. S. (2000) Voltage-dependent ion
channels in CAD cells: A catecholaminergic neuronal line that exhibits
inducible differentiation. J. Neurophysiol. 84, 2888–2895.
(27) Wang, Y., Park, K. D., Salome, C., Wilson, S. M., Stables, J. P.,
Liu, R., Khanna, R., and Kohn, H. (2011) Development and character-
ization of novel derivatives of the antiepileptic drug lacosamide that
exhibit far greater enhancement in slow inactivation of voltage-gated
sodium channels. ACS Chem. Neurosci. 2, 90–106.
(28) Lee, B. H., Won, R., Baik, E. J., Lee, S. H., and Moon, C. H.
(2000) An animal model of neuropathic pain employing injury to the
sciatic nerve branches. NeuroReport 11, 657–661.
(29) Salome, C., Salome-Grosjean, E., Park, K. D., Morieux, P.,
Swendiman, R., DeMarco, E., Stables, J. P., and Kohn, H. (2010)
Synthesis and anticonvulsant activities of (R)-N-(40-substituted)benzyl
2-acetamido-3-methoxypropionamides. J. Med. Chem. 53, 1288–1305.
(30) Swinyard, E. A. (1969) Laboratory evaluation of antiepileptic
drugs: review of laboratory methods. Epilepsia 10, 107–109.
(31) Paverello, P., Bonsignori, A., Caccia, C., Amici, R., McArthur,
R. A., Fariello, R. G., Salvatti, P., and Varasi, M. (1999) Sodium channel
activity and sigma binding of 2-aminopropanamide anticonvulsants.
Bioorg. Med. Chem. Lett. 9, 2521–2544.
(32) Fariello, R. G., McArthur, R. A., Bonsignori, A., Cervini, M. A.,
Maj, R., Marrari, P., Pevarello, P., Wolf, H. H., Woodhead, J. W., White,
H. S., Varasi, M., Salvati, P., and Post, C. (1998) Preclinical evaluation of
PNU-151774E as a novel anticonvulsant. J. Pharmacol. Exp. Ther.
285, 397–403.
(33) For comparable procedures for resolving stereoisomers, see the
following: (a) Weisman, G. R. (1983) In Asymmetric Synthesis-Analytical
Methods (Morrison, J. D., Ed.), Vol. 1, pp 153171, Academic Press,
New York. (b) Parker, D., and Taylor, R. J. (1987) Direct 1HNMR assay
of the enantiomeric composition of amines and β-amino alcohols using
O-acetyl mandelic acid as a chiral solvating agent. Tetrahedron 43,
5431–5456.
(34) Wang, Y., Brittain, J. M., Jarecki, B. W., Park, K. D., Wilson,
S. M., Wang, B., Hale, R., Meroueh, S. O., Cummins, T. R., and Khanna,
R. (2010) In silico docking and electrophysiological characterization of
lacosamide binding sites on collapsin response mediator protein-2
identifies a pocket important in modulating sodium channel slow
inactivation. J. Biol. Chem. 285, 25296–25307.
(35) Rudy, B. (1978) Slow inactivation of the sodium conductance
in squid giant axons. Pronase resistance. J. Physiol. 283, 1–21.
(36) Hodgkin, A. L., and Huxley, A. F. (1952) The dual effect of
membrane potential on sodium conductance in the giant axon of Loligo.
J. Physiol. 116, 497–506.
(37) Bean, B. P. (2007) The action potential in mammalian central
neurons. Nat. Rev. Neurosci. 8, 451–465.
(38) Do, M. T., and Bean, B. P. (2003) Subthreshold sodium
currents and pacemaking of subthalamic neurons: modulation by slow
inactivation. Neuron 39, 109–120.
(39) Vilin, Y. Y., and Ruben, P. C. (2001) Slow inactivation in
voltage-gated sodium channels: molecular substrates and contributions
to channelopathies. Cell Biochem. Biophys. 35, 171–190.
(40) Catterall, W. A. (2002) Molecular mechanisms of gating and
drug block of sodium channels. Novartis Found. Symp. 241, 206218,
discussion 218232.
(41) Leach, M. J., Marden, C. M., and Miller, A. A. (1986) Pharma-
cological studies on lamotrigine, a novel potential antiepileptic drug: II.
Neurochemical studies on the mechanism of action. Epilepsia 490–497.
(42) Woodbury, D. M. (1980) Phenytoin: proposed mechanism of
anticonvulsant action. Adv. Neurol. 27, 447–471.
(43) Barnes, S., and Hille, B. (1988) Veratridine modifies open
sodium channels. J. Gen. Physiol. 91, 421–443.
(44) Ulbricht, W. (1998) Effects of veratridine on sodium currents
and fluxes. Rev. Physiol., Biochem., Pharmacol. 133, 1–54.
(45) Wang, Y, and Khanna, R. (2011) Voltage-gated calcium chan-
nels are not affected by the novel anti-epileptic drug lacosamide. Transl.
Neurosci. 2, 13–22.
(46) Decosterd, I., Allchorne, A., andWoolf, C. J. (2004) Differential
analgesic sensitivity of two distinct neuropathic pain models. Anesth.
Analg. 99, 457–463.
(47) Filatov, G. N., and Rich, M. M. (2004) Hyperpolarized shifts in
the voltage dependence of fast inactivation of Nav1.4 and Nav1.5 in a rat
model of critical illness myopathy. J. Physiol. 559, 813–820.
(48) Rich, M. M., and Pinter, M. J. (2003) Crucial role of sodium
channel fast inactivation in muscle fibre inexcitability in a rat model of
critical illness myopathy. J. Physiol. 547, 535–566.
(49) Jarecki, B. W., Sheets, P. L., Jackson, J. O., and Cummins, T. R.
(2008) Paroxysmal extreme pain disorder mutations within the D3/S4-
S5 linker of Nav1.7 cause moderate destabilization of fast inactivation.
J. Physiol. 586, 4137–4153.
(50) Backonja,M.M. (2002) Use of anticonvulsants for treatment of
neuropathic pain. Neurology 59, S14–S17.
(51) Challopalli, V., Tremont-Lukats, I. E., McNicol, E. D., Lau, J.,
and Carr, D. B. (2005) Systemic administration of local anesthetic agents to
relieve neuropathic pain. Cochrane Database Syst. Rev. CD003345.
(52) Hildebrand,M. E., Smith, P. L., Bladen, C., Eduljee, C., Xie, J. Y.,
Chen, L., Fee-Maki, M., Doering, C. J., Mezeyova, J., Zhu, Y., Belardetti,
F., Pajouhesh, H., Parker, D., Arneric, S. P., Parmar, M., Porreca, F.,
Tringham, E., Zamponi, G. W., and Snutch, T. P. (2011) A novel slow-
inactivation-specific ion channel modulator attenuates neuropathic pain.
Pain 152, 833–843.
(53) Vissers, K. C. P., Geenen, F., Biermans, R., and Meet, T. F.
(2006) Pharmacological correlation between the formalin test and the
neuropathic pain behavior in different species with chronic constriction
injury. Pharmacol., Biochem. Behav. 84, 479–486.
(54) Wang, Y., Brittain, J. M., Wilson, S. M., Hingtgen, C. M., and
Khanna, R. (2010) Altered calcium currents and axonal growth in Nf1
haploinsufficient mice. Transl. Neurosci 1, 106–114.
332 dx.doi.org/10.1021/cn200024z |ACS Chem. Neurosci. 2011, 2, 317–332
ACS Chemical Neuroscience RESEARCH ARTICLE
(55) Taylor, A. L., and Hewett, S. J. (2002) Potassium-evoked
glutamate release liberates arachidonic acid from cortical neurons.
J. Biol. Chem. 277, 43881–43887.
(56) Kuo, C.-C., and Bean, B. P. (1994) Slow binding of phenytoin
to inactivated sodium channels in rat hippocampal neurons. Mol.
Pharmacol. 46, 716–725.
